Oxford Immunotec Global PLC Form SC 13G/A August 21, 2017

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### **SCHEDULE 13G**

# INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO

**RULE 13d-2** 

(Amendment No. 1)

**Oxford Immunotec Global PLC** 

(Name of Issuer)

**Ordinary Shares** 

(Title of Class of Securities)

G6855A103

(CUSIP Number)

June 2, 2017

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

#### Edgar Filing: Oxford Immunotec Global PLC - Form SC 13G/A



(1) The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. G6855A103 Page 2 of 10 Pages

#### Schedule 13G

Item 1(a). Name of Issuer:

Oxford Immunotec Global PLC (the Issuer ).

#### Item 1(b). Address of Issuer s Principal Executive Offices:

The Issuer s principal executive offices are located at 94C Innovation Drive, Milton Park, Abingdon, OX14 4RZ, United Kingdom.

#### Item 2(a). Name of Persons Filing:

This joint statement on Schedule 13G is being filed by New Leaf Ventures II, L.P. ( NLV II ), New Leaf Venture Associates II, L.P. ( NLV Associates ) and New Leaf Venture Management II, L.L.C. ( NLV Management and together with NLV II and NLV Associates, the Reporting Entities ) and Vijay Lathi ( Lathi ), Ronald Hunt ( Hunt ), Jeani Delagardelle ( Delagardelle ) and Liam Ratcliffe ( Ratcliffe and together with Lathi, Hunt and Delagardelle, the Managing Directors ). The Reporting Entities and the Managing Directors collectively are referred to as the Reporting Persons .

#### Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of NLV II, NLV Associates, NLV Management, Hunt and Ratcliffe is New Leaf Venture Partners, Times Square Tower, 7 Times Square, Suite 3502, New York, NY 10036. The address of the principal business office of Lathi and Delagardelle is New Leaf Venture Partners, 1200 Park Place, Suite 300, San Mateo, CA 94043.

#### Item 2(c). Citizenship:

Each of NLV II and NLV Associates is a limited partnership organized under the laws of the State of Delaware. NLV Management is a limited liability company organized under the laws of the State of Delaware. Each Managing Director is a citizen of the United States.

Item 2(d). Title of Class of Securities:

Ordinary shares ( Ordinary Shares ).

Item 2(e). CUSIP Number:

G6855A103

## Edgar Filing: Oxford Immunotec Global PLC - Form SC 13G/A

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

Not applicable.

CUSIP No. G6855A103 Page 3 of 10 Pages

#### Item 4. Ownership.

Each Reporting Person has ceased to beneficially own five percent (5%) or more of the Issuer s outstanding Ordinary Shares.

### Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

#### Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

# Item 7. <u>Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.</u>

Not applicable.

#### Item 8. <u>Identification and Classification of Members of the Group</u>.

Not applicable.

#### Item 9. Notice of Dissolution of Group.

Not applicable.

#### Item 10. Certification.

Not applicable. This Schedule 13G is not filed pursuant to Rule 13d-1(b) or Rule 13d-1(c).

#### Material to be Filed as Exhibits.

Exhibit 1 Agreement regarding filing of joint Schedule 13G.

Exhibit 2 Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

CUSIP No. G6855A103 Page 4 of 10 Pages

#### **SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 21, 2017

NEW LEAF VENTURES II, L.P.

By: NEW LEAF VENTURE ASSOCIATES II, L.P.

General Partner

By: NEW LEAF VENTURE MANAGEMENT II, L.L.C.

General Partner

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

NEW LEAF VENTURE ASSOCIATES II, L.P.

By: NEW LEAF VENTURE MANAGEMENT II, L.L.C.

General Partner

By: /s/ Craig L. Slutzkin

Craig L. Slutzkin Chief Financial Officer

NEW LEAF VENTURE MANAGEMENT II,

L.L.C.

By: /s/ Craig L. Slutzkin Craig L. Slutzkin Chief Financial Officer

\*

Vijay Lathi

\*

Ronald Hunt

\*

Jeani Delagardelle

\*

Liam Ratcliffe

CUSIP No. G6855A103 Page 5 of 10 Pages

\*/s/ Craig L. Slutzkin Craig L. Slutzkin As attorney-in-fact

<sup>\*</sup> This Schedule 13G was executed by Craig L. Slutzkin on behalf of the individuals listed above pursuant to Powers of Attorney, copies of which are attached as Exhibit 2.